By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


The Journal of the American Medical Association 

515 North State Street

Chicago  Illinois  60610  U.S.A.
Phone: 312-464-5000 Fax:



Company News
AVANIR Pharmaceuticals (AVNR) Announces JAMA Publication Of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation In Patients With Alzheimer's Disease 9/23/2015 11:07:18 AM
50 Percent Of U.S. Adults Have Diabetes Or Pre-Diabetes, JAMA Reveals 9/9/2015 7:11:11 AM
JAMA Release: Multigene Panel Testing For Hereditary Breast/Ovarian Cancer Risk Assessment 8/13/2015 10:02:24 AM
JAMA Publishes Long-Term Safety And Efficacy Results Of Trial With Relypsa (RLYP)'s Patiromer FOS Over One Year 7/14/2015 1:22:31 PM
Ethicists From NYU Langone Medical Center Propose Solution For U.S. Organ Shortage Crisis In JAMA Piece 5/11/2015 4:33:07 PM
Another Study Finds No Link Between MMR Vaccine And Autism, JAMA Reveals 4/22/2015 6:29:50 AM
Janssen Research & Development Release: New Study Published In JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time To Relapse In Patients With Schizophrenia 3/30/2015 9:04:13 AM
XBiotech USA, Inc. Announces Phase II Psoriasis Study Results in JAMA Dermatology 3/5/2015 6:51:18 AM
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015 11:21:14 AM
Results from AbbVie (ABBV)'s Study Of VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) Published Online In JAMA; Sub-Analyses To Be Presented At The Annual Conference On Retroviruses And Opportunistic Infections (CROI) 2/23/2015 9:33:09 AM